Kornimate/medical-research-clean huggingface dataset:
genetics of ankylosing spondylitis

Conditions: Spondylitis; Ankylosing Spondylitis

Summary: ankylosing spondylitis (as) is a chronic inflammatory disease that affects the joints between the vertebrae of the spine and the joints between the spine and the pelvis. the purpose of this study is to collect information and blood samples from patients with as and their relatives for use in genetic studies.

as is a chronic inflammatory disease that eventually causes the affected vertebrae to fuse or grow together. the cause of as is unknown, but genetic factors seem to play a role. risk factors include a family history of ankylosing spondylitis and male gender. this study will collect patient information and blood samples from affected patients (and when available, both parents of the affected patients) of 400 families with children fulfillling the modified new york criteria for as. diagnosis of as will be verified by patient questionnaire, medical record review, and pelvic radiographs. information from these patients will be used to search the human genome for disease-associated loci and/or genes. this study will also utilize contributions of investigators who have conducted recent clinical or genetic research in as at 10 academic medical centers throughout north america (the north american spondylitis consortium, or nasc).

Eligibility criteria:
inclusion criteria: * meet modified new york criteria for ankylosing spondylitis (as) * as as confirmed by x-rays of sacroiliac joints (between the pelvis and spine) * at least two siblings in family with as * parents of the participants with as have the option of also being enrolled
first experimental study of transference-interpretations (fest)

Conditions: Mood Disorders; Anxiety Disorders; Personality Disorders

Summary: analysis of the ongoing patient-therapist interaction, the transference, is considered a key active ingredient in psychoanalytically oriented psychotherapy and psychoanalysis.however, one century after sigmund freuds's famous "dora" case, the first clinical description of transference, no study of transference interpretations have been published.in the present study 100 out-patients were randomized to receive one year weekly dynamic psychotherapy, with and without transference interpretations. that is, one treatment component,transference interpretations, were added to a comparison condition, therapy of the same format, by the same therapists, but without use of transference interpretation. all treatment session were audiotaped, and treatment integrity have been carefully checked. patients were evaluated at treatment termination, one year after treatment termination and three years after treatment termination. enrollment of patients started january 1993, and all follow-up evaluations completed by december 2005.

this study is designed to measure specific long-term effects of transference interpretations in dynamic psychotherapy, using an experimental dismantling design. one hundred psychiatric out-patients, referred to seven study therapists, to receive exploratory dynamic psychotherapy, were randomized to one year weekly dynamic psychotherapy, with and without transference interpretations.they suffered from mood,anxiety,and personality disorders or interpersonal problems not due to a mental disorder. all treatment sessions were audiotaped and treatment integrity carefully checked.all patients have been evaluated before treatment, after treatment, one year after termination of treatment, and three years after termination of treatment. the main outcome measures were the psychodynamic functioning scales (pfs) and inventory of interpersonal problems-circumplex version (iip-c).chang over time is assessed using linear mixed model analyses. the main hypothesis is that patients treated with transference interpretations will have a more favourable course over the whole study period of four years. the second hypothesis is that suitable patients, that is patients with a life long pattern of more mature object relations (qor) and/or patients without comorbid personality disorders will do better with transference interpretations. insight and identification with the therapist will be analyzed as putative mediators of long-term change in interpersonal functioning

Eligibility criteria:
inclusion criteria: * age 20 - 60 years * diagnoses mood-disorder, non-psychotic * anxiety disorders * personality disorders * interpersonal problems not due to a mental disorder exclusion criteria: * psychotic disorders * bipolar disorder * organic brain disorder * substance abuse * long-term (years) disability * mental retardation

Keywords: psychotherapy long-term effects
balloon remodeling antrostomy therapy study

Conditions: Sinusitis

Summary: this study is designed to evaluate safety and effectiveness of a less invasive procedure to treat maxillary only, or maxillary and anterior ethmoid, chronic sinusitis. additionally, this study will assess the feasibility of performing the procedure under local anesthesia.


Eligibility criteria:
inclusion criteria: * subjects age 18 or older with chronic rhinosinusitis of the maxillary or maxillary and anterior ethmoid sinuses * a ct scan taken after maximal medical therapy (e.g., local or systemic antibiotics, topical steroids, etc.) must show one of the following: 1. narrowing of the outflow tract of the maxillary sinus ostium or infundibulum with mucosal thickening of 2 mm or greater of the maxillary sinus antrum. 2. evidence of maxillary sinus air/liquid level. exclusion criteria: * evidence of chronic posterior ethmoid, sphenoid or frontal sinusitis * inability to understand the study or a history of non-compliance with medical advice * unwilling or unable to sign informed consent form (icf) * currently enrolled in any other pre-approval investigational study (does not apply to long-term post-market studies) * history of any cognitive or mental health status that would interfere with study participation * previous sinus surgery or intervention including sinuplasty * pregnant women * severe septal deviation causing obstruction of the ostiomeatal unit * history of primary ciliary dysfunction * hemophilia * currently undergoing or in the past 6 months had undergone chemotherapy for cancer or radiation therapy in the head or neck region * history of cystic fibrosis * known sampter's triad (aspirin sensitivity, asthma, sinonasal polyposis) * known sinonasal tumors or obstructive lesions * history of mid facial fractures or orthognathic surgery (does not include nasal fracture) * history of insulin dependent diabetes * not able to stop anti-coagulant (e.g., warfarin) until the international normalized ratio(inr) is below 1.5 * not able to stop anti-platelet (e.g., clopidogrel, aspirin, etc.) for at least 14 days prior to study procedure * not able to stop any non-steroidal anti-inflammatory medications and homeopathic medications for at least 14 days prior to the study procedure * presence of nasal polyps that may interfere with the treatment procedure * presence of features consistent with sinus fungal disease on ct or physical examination

Keywords: chronic rhinosinusitis chronic sinusitis maxillary sinus anterior ethmoid sinus ethmoid infundibulum balloon dilation endoscopic visualization local anesthesia canine fossa less invasive
chronic non-specific neck pain and quality of life

Conditions: Neck Pain; Quality of Life

Summary: the factors affecting the quality of life in individuals with chronic non-specific neck pain are not fully known in the studies conducted to date. the aim of this study was to examine the factors affecting the quality of life of individuals with chronic non-specific neck pain.


Eligibility criteria:
inclusion criteria: no history of radicular pain, trauma or surgery in the cervical region, * between the ages of 18-65, * having neck pain for at least 6 months, * not having received any treatment for neck pain in the last year * volunteers with chronic non-specific neck pain exclusion criteria: * those with any systemic disease * those with cervical pathology * previous surgery in the neck region * those with neuromuscular disease * those with rheumatology disease * infection

Keywords: chronic neck pain quality of life depression proprioception muscle strength
study of airway physiology in adults. seretide diskus® inhaler and flixotide® inhaler are trademarks of gsk croup of companies.

Conditions: Asthma

Summary: comparison of two asthma treatments by lung function measures.

single centre, randomised, double-blind, comparator study to demonstrate superiority of salmeterol/fluticasone propionate combination product 50/100mcg bd over fluticasone propionate 100mcg bd with respect to improvements in airway physiology (sraw) in adults with persistent asthma treated for 4 weeks.

Eligibility criteria:
inclusion: * physician documented diagnosis of asthma which has been present for at least 6 months. * receiving a total daily dose of 200-500mcg/day beclomethasone dipropionate or equivalent for at least 4 weeks prior to the start of the run-in period. exclusion: * has had 3 or more courses of oral corticosteroids in the 12 months previous to visit 1

Keywords: inhaled corticosteroids asthma
pfna vs dual mobility in treatment of unstable trochanteric fractures

Conditions: Trochanteric Fractures

Summary: proximal femoral nail \[pfna\] versus dual mobility arthroplasty in treatment of unstable trochanteric fractures

compare clinial outcome between two different procdures either using pfna or arthroplasty in the treatment of unstable trochaneric fractures

Eligibility criteria:
inclusion criteria: * patients with trochanteric unstable fractures. * age 60 or above * recent fracture time within 2 weeks time period * trochanteric starting point in pfna * patients medical condition is stable exclusion criteria: * stable trochanteric fractures * delayed or neglected fractures * unstable patients medical conditions * pirformis fossa starting point in pfna
a study of abt-263 in participants with relapsed or refractory chronic lymphocytic leukemia

Conditions: Chronic Lymphocytic Leukemia

Summary: the phase 1 portion of the study will evaluate the pharmacokinetic profile and safety of abt-263 under two different dosing schedules with the objective of defining the dose limiting toxicity and maximum tolerated dose. the phase 2a portion of the study will evaluate abt-263 at the defined recommended phase 2 dose to obtain additional safety information and a preliminary assessment of efficacy. the extension study portion will allow active subjects to continue to receive abt-263 for up to 11 years after the last subject transitions with less frequent study evaluations.


Eligibility criteria:
inclusion criteria: * relapsed or refractory cll and require treatment in opinion of investigator. * eastern cooperative oncology group (ecog) \<= 1. * adequate bone marrow independent of growth factor support, renal and hepatic function per defined laboratory criteria. exclusion criteria: * history or is clinically suspicious for cancer-related central nervous system disease. * receipt of allogenic or autologous stem cell transplant. * recent history (within 1 year of first dose) of underlying, predisposing condition of bleeding or currently exhibits signs of bleeding. * active peptic ulcer disease or other potentially hemorrhagic esophagitis/gastritis. * active immune thrombocytopenic purpura or history of being refractory to platelet transfusions (within 1 year of first dose).

Keywords: chronic lymphocytic leukemia (cll) navitoclax abt-263 cancer
comparison of ulcer healing in patients taking rabeprazole with different antiplatelets

Conditions: Gastric Ulcer; Duodenal Ulcer

Summary: clopidogrel causes significantly less peptic ulcer disease (pud) and ulcer bleeding than low-dose aspirin in general population. however, clopidogrel is not safe enough for gastrointestinal (gi) mucosa in patients who had past history of aspirin-associated ulcer or ulcer bleeding. aspirin plus proton pump inhibitor (ppi) is superior to clopidogrel alone in preventing recurrent ulcer bleeding in these high risk patients. this study is to compare the ulcer healing rate and ulcer bleeding at 12 weeks in patients with aspirin-associated pud when they take ppi (rabeprazole 20 mg/day) to treat their pud and simultaneously take aspirin or clopidogrel for their cardiovascular (cv) prevention. two hundred patients will be randomly assigned rabeprazole (20 mg/day) plus aspirin (100 mg/day) or rabeprazole (20 mg/day) plus clopidogrel (75 mg/day) for 12 weeks. the primary end point is treatment success (ulcer healing rate). the secondary end point is incidence of ulcer bleeding within 12 weeks. if rabeprazole plus aspirin in not inferior to rabeprazole plus clopidogrel in the incidence of ulcer healing and ulcer bleeding in the healing phase,ppi plus aspirin rather than ppi plus clopidogrel will be recommended during acute ulcer healing in patients who need antiplatelet therapy for their cv prevention.


Eligibility criteria:
inclusion criteria: * patients who have taken aspirin for more than 1 month and are found to have pud by upper endoscopy will receive ppi (rabeprazole 20 mg once daily) to treat their pud. pud in the upper gastrointestinal (ugi) tract is defined as * \[1\] mucosal break of stomach or duodenum \> 3 mm in diameter; or * \[2\] more than 10 gastric or duodenal erosions, without malignancy proved by histopathological examination. exclusion criteria: * patients will be excluded if they have pud with bleeding (ulcer with adherent blood clot, visible vessel, oozing, or spurting) requiring endoscopic hemostasis, * if they take other antithrombotic or anticoagulants simultaneously, if they have take nsaids, selective cox-2 inhibitors, or steroid, * if they have take misoprostol or histamine receptor-2 antagonist (h2ra), * if they have bleeding tendency (thrombocytopenia with platelet count \ 5 seconds), * if they have anemia (hemoglobin \< 10 g/dl), * if they have received a surgical intervention due to pud complication (bleeding, perforation, obstruction) in the past, * if their age are \> 80 year-old or \< 18 year-old, * if they have severe cardiovascular, pulmonary, hepatic, or renal disease.

Keywords: aspirin, clopidogrel, peptic ulcer, proton pump inhibitor, rabeprazole, ulcer bleeding
a comparative study on relieving postpartum lumbago with fire-dragon cupping therapy and acupuncture

Conditions: Postpartum Low Back Pain; Acupuncture; Core Stability Training; Huolong Tank

Summary: abstract: objective to compare the effects of fire dragon pot therapy and acupuncture on low back pain, lumbar function, self-efficacy and postpartum depression in patients with postpartum low back pain. methods from april 2024 to september 2024, 84 postpartum patients with low back pain who met the standard of sodium discharge in hangzhou area were recruited and divided into acupuncture group (routine acupuncture + core stability training (42 cases) and huolongcan group (42 cases) according to random number table method. fire dragon pot + core stability training (42 cases), the two groups each intervention 30 min, once every other day, intervention 3 times. before and after the intervention, the visual analogue scale (vas) was used to evaluate the degree of low back pain, the oswestry disability index (odi) was used to evaluate the lumbar function, the pain self-efficacy questionnaire (pseq) was used to evaluate the patients' confidence in effectively coping with pain, and the edinburgh postpartum depression scale (epds) was used to evaluate the postpartum depression. the changes of each index before and after intervention were observed.


Eligibility criteria:
inclusion criteria: * (1) postpartum 42 days to 1 year; (2) visual analogue scale (vas)\[7\]≥4 points; (3) have basic reading comprehension ability, be able to fill out questionnaires independently, cooperate with investigation and treatment; (4) sign informed consent voluntarily. exclusion criteria: * (1) tumor, fracture, tuberculosis, bleeding tendency or serious organic disease; (2)immune system diseases such as ankylosing spondylitis; (3) severe osteoporosis; (4) patients with yin deficiency and fire flourishing
neoadjuvant study of pyrotinib in combination with trastuzumab in patients with her2 positive breast cancer

Conditions: HER2-positive Breast Cancer

Summary: this is a randomised, double-blind multicenter phase iii study for evaluating the efficacy and safety of neoadjuvant pyrotinib and trastuzumab plus docetaxel versus placebo and trastuzumab plus docetaxel given as neoadjuvant treatment in her2 positive early stage or locally advanced breast cancer.


Eligibility criteria:
inclusion criteria: * female patients, 18 years ≤ age ≤ 75 years； * performance status- eastern cooperative oncology group (ecog) 0-1 * histologically confirmed invasive breast cancer（early stage or locally advanced）:primary tumour greater than 2 cm diameter * her2 positive (her2+++ by ihc or fish+) * known hormone receptor status. * cardiovascular:baseline left ventricular ejection fraction (lvef)≥55% measured by echo * signed informed consent form (icf) exclusion criteria: * metastatic disease (stage iv) or inflammatory breast cancer * previous or current history of malignant neoplasms, except for curatively treated:basal and squamous cell carcinoma of the skin,carcinoma in situ of the cervix. * clinically relevant cardiovascular disease:known history of uncontrolled or symptomatic angina, clinically significant arrhythmias, congestive heart failure, transmural myocardial infarction, uncontrolled hypertension ≥180/110); * unable or unwilling to swallow tablets.
an evaluation of the causes of anemia in patients with heart failure

Conditions: Anemia; Heart Failure; Chronic Renal Failure

Summary: anemia is frequent in patients with heart failure. few studies have clearly addressed the causes of anemia in patients with hf. the purpose of this study is to evaluate differences in blood concentrations of various substances related to inflammation, oxidative stress, renal function and other processes between individuals with 1) heart failure and anemia, 2) heart failure without anemia and 3) patients with kidney disease without systolic heart failure. this study will help to better understand the reasons why some people with heart failure have anemia.


Eligibility criteria:
inclusion criteria: groups 1 and 2 * age \>18 years * group 1: hemoglobin \< 120g/l in women and \< 130 g/l in men (in agreement with the who definition of anemia) * group 2: hemoglobin \> or = 120g/l in women and \> or = 130 g/l in men * patients with chronic hf referred to a specialized hf clinic, or with a diagnosis of hf at least 6 months prior to enrolment * nyha functional class ii-iv at the time of enrolment * patients already on chf medical therapy (acei or arbs, beta-blockers if tolerated, with or without digoxin, and loop diuretics), at stable doses for \> or = 1 month * lvef \< or = 40% within 6 months prior to patient enrolment, by echocardiography, radionuclide ventriculography or perfusion scan, or radiologic angiography inclusion criteria - group 3 * age \>18 years * at least moderate crf (egfr \< 60ml/min/1,73m2) * with or without anemia * lvef \> or = 50% within 6 months prior to patient enrolment, by echocardiography, radionuclide ventriculography or perfusion scan, or radiologic angiography exclusion criteria (all groups): * recent acute renal failure episode (\< 1 month) * red blood cells (or other blood component) transfusions or epo therapy within 3 months prior to enrolment * iron, b12 or folic acid supplements used to treat anemia (\< 3 months) * evidence of active gi bleeding * recent acute coronary syndrome or decompensated hf episode (\< 1 month) * complex congenital heart disease * known malignant hematologic or other active neoplasia * immunosuppressive therapy, chemotherapy or radiotherapy within 3 months prior to enrolment * recent acute decompensation of a chronic inflammatory disease (e.g. chronic inflammatory bowel disease, rheumatoid arthritis, collagen vascular disease) within 3 months prior to enrolment * recent viral or bacterial syndrome (\< 2 weeks) * active or recent viral hepatitis (\< 3 months) * pregnant women * potential for non compliance to tests involved in this protocol * incapacity to provide informed consent

Keywords: inflammation oxidative stress estimated glomerular filtration rate
extra short implants brånemark system® rp ø4.5x4.5 mm implants

Conditions: Healthy Volunteers With Severely Resorbed Jaws in Need of an Implant Supported Restoration

Summary: an extra short, 2-piece implant with a brånemark hexagon interface was developed with a bone anchoring length of only 4.5 mm, for subjects with severely resorbed jaws.


Eligibility criteria:
inclusion criteria: * the subject should be at least 18 years of age and have passed secession of growth * the subject should be in need of an implant-supported restoration in the posterior region of the mouth (maxilla: first premolar to third molar, mandible: first premolar to second molar, not third molar due to mobile gingiva), where at least 2 implants are needed of which at least one should be an extra short implant * obtained informed consent from the subject * the subject must be in such a physical and mental condition that a 5-year follow-up period can be carried out without foreseeable problems * the subject should have a severely resorbed posterior mandible and/ or maxilla. * implants are only to be placed in healed sites, defined as a site with minimum 6 months of healing following tooth extraction * at least 6 mm residual bone width, between 4-7 mm residual bone height in the maxilla and between 6-9 mm residual bone height in the mandible * at implant installation the implant should be stable; final tightening torque of the implant about 25 ncm or higher, preferably not exceeding 45 ncm * the subject should be healthy and compliant with good oral hygiene * favorable and stable occlusal relationship exclusion criteria: * the subject is not able to give her/his informed consent of participating * health conditions, which do not permit the surgical treatment * reason to believe that the treatment might have a negative effect on the subject's total situation (psychiatric problems), as noted in subject records or in subject history * any disorders in the planned implant area such as previous tumours, chronic bone disease or previous irradiation * alcohol or drug abuse as noted in subject records or in subject history. * heavy smoking (\>10 cigarettes/day) * intake of medication containing bisphosphonates * uncontrolled diabetes, i.e. a subject with diagnosed diabetes that has a history of neglecting doctor's recommendations regarding treatment, food and alcohol intake * severe bruxism or other destructive habits * immediate insertion (i.e. placement of the implant immediately after extraction) * bone augmentation procedures before or at implant installation is not allowed * deviation from stated drilling protocol, utilizing osteotomes, is not allowed * lack of opposing dentition * single crown restorations are not to be performed in the study

Keywords: short implants nobel biocare partially edentulous maxilla or mandible